MUSTANG BIO INC
MBIONASDAQ🏆 #3763 by market capUS Equity
$0.61▲ $0.03 (+5.01%)
Live1h—
24h▲ 5.0%
7d▲ 8.9%
14d▼ 7.7%
30d▼ 12.3%
1y▼ 65.5%
🏦Market Cap
$5M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
49
Weak
Trading Snapshot
- Day Range
- $0.60 – $0.61
- 52-Week Range
- $0.53 – $1.88
- Volume
- $2.13B
- Avg Volume
- $2.25B
- Shares Outstanding
- 7.6M
- Next Earnings
- Oct 14, 2026
Fundamentals Snapshot
- Annual Revenue
- $371,665
- Last Q Revenue
- $98,534
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-0.49
- Dividend Yield
- —
Why Investors Own MBIO
- ✓High-growth profile — revenue up +57.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 28% gross margin and 15% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$371,665▲ +54.6% YoY
Gross Margin (TTM)
27.5%▲ +3.9% YoY
Operating Income (TTM)
$87,341▲ +54.6% YoY
Free Cash Flow (TTM)
$54,263▲ +54.6% YoY
About MUSTANG BIO INC
A company profile for MUSTANG BIO INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
49/100
Analyst Ratings
ⓘConsensus
Buy
7 analysts
Strong Buy2
Buy4
Hold1
Sell0
Strong Sell0
Ratings as of Dec 2024
Latest News & Updates
🚀
CNBC·2h ago
MUSTANG BIO INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Reuters·5h ago
Analysts lift MBIO price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Barron’s·1d ago
MUSTANG BIO INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.